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3. 1
, i $(i=1,\ldots,n)$ Xi
$\text{ }\mathrm{Y}_{i}\text{ }$ , .
$X_{i}\sim N(\mu_{1},\sigma_{1}^{2})$ , $Y_{i}\sim N(\mu_{2},\sigma_{2}^{2})$
, nl , {\sim h
.
, S $(s=1,2)$ i $(i=1,\ldots,n_{s})$
A, B, ,
.
$A_{i}\sim Bemoulli(p_{A})$ , $B_{i}\sim Bernoulli(p_{B})$
, $X_{l}$ $A_{i}$ $\mathrm{Y}_{i}$ $B_{i}$ , $\Lambda_{i}$ $B_{i}$
$\tilde{A}_{t},\tilde{B}_{i}\text{ }$ . $\text{ }\tilde{A}_{i},\tilde{B}_{i}\text{ }$
76
.$\tilde{A}_{i}\sim N(\nu_{1},\tau_{1}^{2})$ , $\tilde{B}_{i}\sim N(\nu_{2},\tau^{\frac{}{2}}’)$
, $A$ , $\tilde{A}\geq 0$ 1, $\tilde{A}<0$ $0$
, $p_{\Lambda}$ ,
$p_{\Lambda}=P(A=1)= \int_{0}^{\infty}f(^{\sim}a\psi_{\mathit{0}}$




X, A, \rho 1 , .
$\sigma_{1}\tau_{1}\rho_{1))}\tau_{1}^{2}$
, , $\tau_{1}^{2}=1/(1-\rho_{1}^{2})$ ,
$\sim N(,(\sigma_{1}^{2}$ $\sigma_{1}\rho_{1}1/(1-\rho_{1}^{2})/\sqrt{1-\rho_{1}^{2}}))$
. , $X_{i}$ $\tilde{A}_{l}$ ,
$\tilde{A}_{i}|X_{i}\sim N(\nu_{1}+\frac{p_{1}(X_{i}-\mu_{1})}{\sigma_{1}\sqrt{1-\rho_{1}^{2}}},1)$




. , $\mathrm{Y}_{j}$ $\tilde{B}_{i}$ $\rho_{2}$ , $\tau_{2}^{2}=1/(1-p^{\frac{7}{2}})$ , ,
77
$\sim N$(
. Yi Bl ,
$\tilde{B}_{i}|\mathrm{Y}_{i}\sim N(\nu_{2}+\frac{p_{2}(\mathrm{Y}_{i}\mu_{2}\rangle}{\sigma_{2}\sqrt{1p_{2}^{2}}}=,1)$










, $\alpha$ , $1-\beta$ .
Z , 1 2
.
$Z= \frac{\sum_{i=1}^{n}B_{i}/n-\sum_{i=1}^{n}A_{i}/n}{\sqrt{\frac{2}{n}\tilde{p}(1-\tilde{p})}}=\frac{\sqrt{n}\mathrm{g}_{i=1}^{n}B_{i}/n\sum_{i=1}^{n}A_{i}/n)}{\sqrt{2\tilde{p}(1\tilde{p})}}=$
, $A_{i}$ , B,
, $P_{A}$ , pB , $n_{1}$ , n2 1
2 , $n=n_{1}+n_{2}$ , , $\tilde{P}$ ,
$\tilde{p}=(\sum_{i=1}^{n}A_{i}+\sum_{i=1}^{n}B_{i})/2n\text{ }$ . n + , , Z
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. , Z\geq za H
, $Z<z_{\alpha}$ , $H_{\mathit{0}}$
.
, Z ,




, $\sigma_{1}^{2}$ $\sigma_{2}^{2}$ , $n_{1}$ 1
. nl , Z ,
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3. 3 l nl
1 n] , Liu &Pledger
. , 1 $n_{1}$
.
$H_{0}$ $(1-\alpha|)$ , $\tilde{Z}<z_{\alpha]}$
. , Hl










. $\text{ }\alpha\sim \text{ }\beta;\text{ }$, 4. 5 .
3. 4 2 $n_{2}$
Liu &Pledger , 2 $n_{2}$ ,
$P_{\mathrm{r}_{\mathrm{m}j\mathrm{n}}}\mathrm{b}\geq z_{\alpha}$ , $\tilde{Z}_{1}\geq z_{\alpha 1}\}\text{ }$ $1-\beta$ , .
, , $1-\beta$ , , $P_{H_{1}}\mathrm{b}\geq z_{\alpha},\tilde{Z}\geq z_{\alpha_{1}}.\}=1-\beta$
.
, Z Z . Z Z ,
$\sim N((_{\sqrt{n}(p_{B}-p_{A})/\sqrt{D}}^{\sqrt{n_{1}}(\mu_{1}-\mu_{2})/\sqrt{\sigma_{1}^{2}+\sigma_{2}^{2}}}),(^{1}$ $\mathrm{c}\mathrm{o}\mathrm{v}[\tilde{Z},Z1?)$ (3. 1)
. , $D=p_{A}(1-p_{A})+p_{B}(1-p_{B}),$ $\mathrm{c}\mathrm{o}\mathrm{v}[\tilde{Z},Z]\text{ }\tilde{Z}\text{ }Z\text{ }$ .

















. , 4. 1 , $P(a_{i}=0|x_{i})$ $P(a_{i}=1|x_{i})$
,
$P(a_{i}=0|x_{i})=1- \Phi(v_{1}+\frac{\rho_{1}(x_{i}\mu_{1})}{\sigma_{1}\sqrt{1p_{1}^{-}}}=,)$ (3. 2)
,




$=r_{-\infty}(x- \mu \mathrm{l}f\Phi(\nu_{1}+\frac{\rho_{1}(x\mu_{1})}{\sigma_{1}\sqrt{1\rho_{1}^{2}}}=)-p_{A}\}f(x\ltimes x$ (3. 4)
. $\text{ }E(\mathrm{Y}-\mu_{2})\cdot(B-p_{B})\text{ }$ ,
$E(\mathrm{Y}-\mu_{2})\cdot(B-p_{B})$
$= \Gamma_{-\infty}^{(_{y-\mu_{2}}l^{\Phi}(\nu_{2}+\frac{\rho_{2}(\gamma-\mu_{2})}{\sigma_{2}\sqrt{1-p_{2}^{2}}})-p_{B}}\int^{f(y\nu_{\mathcal{Y}}}$ (3. 5)
.
, Z Z . ,
$P_{H_{1b\iota\Gamma_{z_{a\downarrow}}\Gamma_{z_{\alpha}}^{f(zz\psi dz=1-\beta}}}\geq_{Z_{a},\tilde{Z}\geq z_{\alpha}\}=}\sim$, (3. 6)
n . , 2 n2 ,
$n_{2}=n-n_{1}$ (3. 7)
.
3. 5 $\alpha_{1^{*}}$ $\beta_{1}$
,
, . ,
$\alpha \mathrm{i}$ $\beta_{1}$ , .
, 2 n\tilde 2 . 1 1





$\delta$ , $P\{\delta=\delta_{\min}\}=\pi$ $P\{\delta=0\}=1-\pi$ .








, $E_{(\pi\rangle}(N)$ $\alpha_{1}^{*}$ $\beta_{1}$ . ,
$\alpha\leq\alpha_{1}^{*}<1$ 0 $<\beta_{1}<\beta$ .
3. 6
3. 6. 1
(3. 1) , (3. 6) $n$ , SAS





$\alpha,$ $\beta,$ $\epsilon_{2}$ $(p_{\Lambda}, p_{B}),$ $\epsilon_{1},$ $\rho_{1},$ $p_{2}$ .
(3. 2) $\langle$ 3. 3) $\nu_{1}$ , $v_{2}$ .
(3. 4) (3. 5) $E(X-\mu_{1})\cdot(A-p_{A})$ $E(\mathrm{Y}-\mu_{2})\cdot(B-p_{B})$
.
$\alpha\leq\alpha-<1$ $0<\beta_{1}^{l}<\beta$ $\alpha|$ $\beta_{1}$
, 1 $n_{1}$ .
SAS probbnrm $n$ $n\geq n_{1}+1$ (3. 6)
$n$ . , probbnrm SAS
.
probbnom$(a,b,p)= \frac{1}{2\pi\sqrt{1-p^{2}}}\mathrm{r}_{-\infty}\mathrm{r}_{-\infty}\exp(-\frac{x^{2}-2\mu y+y\underline’}{2(1-\rho^{2})})dxdy$
(3. 7) $n_{2}$ , (3. 8) $E_{(\pi\rangle}(N)$ .
83
$E_{\langle\pi\rangle}$ (N) $\alpha_{1}^{*}$ $\beta_{\mathrm{l}}^{\mathrm{g}}$ $\alpha_{1}$ $\beta_{1^{*}}$ , $n$
. , $\text{ }n_{20}\text{ }3$ . 6. 3 ,
$n_{20}=50\text{ }$ . \mbox{\boldmath $\pi$} , , $\pi=0.5$
.
\alpha , $\beta,$ $\epsilon_{2}(p_{A},$ $P_{B}\rangle$ , $\epsilon_{1},$ $P\iota$ ’\rho 2 n,










1 $\rangle$ 2 , 1
.
2) 1 (12 ) .
3) , , , ,
, 6 .
4) 25 . ,
3 , $n_{20}=50$
. 2 , 25
.




; $E_{H1}(N)=n_{1}+\beta_{1}^{*}\cdot n_{20}+(1-\beta_{1}^{\mathrm{r}})\cdot n_{2}$
; $E_{\text{ }H1}(N)=n_{c1}+(1-\beta)\cdot n_{c2}$
; $E_{H1}(T)=(^{n}1/_{25^{+3}})+(1-\beta_{1})\cdot\{^{(n_{2}-n_{20/}})_{25}+12\}$
; $E_{cH1}(T)=(^{n_{c}}/125^{+6)+}(1-\beta)\cdot \mathrm{t}^{n_{c}}/225^{+12\}}$
; $E_{H\text{ }}(N)=n_{1}+(1-\alpha_{1}’)\cdot n_{2\text{ }}+\alpha_{1}^{*}\cdot n_{2}$
; $E_{\text{ }H0}(N)=n_{c1}+\alpha\cdot n_{c2}$
; $E_{H0}(T)=(^{n}1/_{25^{+3}})+\alpha_{1}^{*}\cdot\{^{(n_{2}-n_{20}}/)_{25^{+12\}}}$
; $E_{\text{ }H0}(T)=(^{n_{c}}/\mathrm{l}25^{+6)+\alpha\cdot\{^{n_{c}}}/225^{+12\}}$










0.4 0.29 87 0.954 0.199 586 91
0.4 0.38 55 0.994 0.034 352 55







02 0.14 0251 0055 238 203 135 1441
03 0.14 0.116 0048 172 96 926 1013
03 022 033 0044 127 91 10 991
03 029 0956 0.197 90 89 1605 983
.——————- $-arrow—$ ————-\sim ---------- $——-$
040140 $0670$037137597 $26\underline{8.65}$72
04 022 0.192 0043 109 54 764 843
$—- 04^{---------}029^{------}0954^{-----}0199^{--------}90^{---------}52^{--}\overline{16.02}$04 029 0954 0199 90 52 1602 835




0.2 014 0251 0055 404 501 2849 3564
0.3 0.14 0.116 0048 401 394 2846 3136
0.3 022 033 0044 174 220 1942 2438
0.3 029 0956 0.197 85 159 1402 2195
0.4 014 0067 0037 397 357 2841 2988
.—————–0.40 $22_{------}0.192_{-----}0043_{-------}174_{-}\underline{183}$22.901942
04 029 0954 0.199 84 122 1397 2047
04 038 0994 0034 55 93 1479 1932
3. 6. 5
3-1 , effect size ,
effect size , $\text{ }(1-\alpha_{1})\text{ }’$ $\tau$
. , .
efffect size , , 2
, - $(1-\alpha[)\text{ }\beta_{1}^{l}\text{ }\mathfrak{l}\mathrm{h}\text{ }$ .
, , , .
3-1 , effect size ,
87
. , effect size
. , effect size
.
3-2 , , effect size
. , 1
.
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